13.12.2023 | Tracker

Product Launch Tracker: eHCPs optimistic about Wegovy competitor’s obesity approval

By Alexandra Maria Chatziioannidou

Every month, CREATION.co’s tracking updates bring you the latest insights from the online conversation of healthcare professionals (eHCPs) across the globe discussing product launches. Discover which new drug approvals eHCPs are talking about, what they think about them, and which online sources they are using to inform their opinions and conversations in CREATION.co’s latest tracking update.


Throughout November 2023 CREATION.co tracked the global conversations of 1,633 eHCPs who posted 2,313 English-language X (formerly Twitter) posts about the launches and approvals of new products.

In November, 166 more eHCPs discussed treatment approvals compared to October and there were 14% more eHCP mentions of new pharmaceutical product launches and drug approvals.

On 8 November, the FDA approved Eli Lilly’s Zepbound (tirzepatide), for chronic weight management for adults with obesity. Tirzepatide, the active ingredient in Zepbound, is already approved under the trade name Mounjaro, for type 2 diabetes. eHCPs were delighted by the news of the approval, as they felt that Zepbound would be a powerful new option offering patients effective treatment. A few eHCPs also commented on Zepbound being priced 20% lower than Wegovy, saying they hope it will lead to better access and sustained lower pricing.

On 16 November, the FDA approved Pfizer and Astellas’ Xtandi (enzalutamide) for non-metastatic castration-sensitive prostate cancer (nmCRPC). Two months prior, on 12 September, the EMA had also approved Xtandi for the same indication. eHCPs showed their excitement around the news on X and also shared the OncoAlert newsletter which was discussing Xtandi’s FDA approval. Dr Chandler Park called the treatment “practice changing” while many other eHCPs congratulated their peers on the EMBARK clinical trial, which was assessing the treatment.

Also on 16 November, the FDA announced the approval of AstraZeneca’s Triqap (capivasertib with fulvestrant) for the treatment of HR+/HER2- metastatic breast cancer. As it was approved, Dr Paolo Tarantino sparked a conversation about a sub-analysis of the CAPItello-291 trial which will be presented at SABCS23. Overall, eHCPs were supportive of the approval as it brings another treatment option for breast cancer patients.

The three most shared stories from eHCPs discussing product launches in November were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.


  • Using CREATION Pinpoint® the English-language X conversations of eHCPs globally discussing new pharmaceutical product launches and drug approvals between 1 November and 30 November 2023 were analysed in order to discover which new product launches eHCPs are discussing as well as #WhatHCPsThink.
  • Mentions of drug approvals by the FDA, EMA, NICE, and CHMP were included in the data, as well as mentions of ‘drug approval’ by eHCPs in their X conversations.
  • Between 1 November and 30 November 2023, there were 2,313 eHCP mentions of new pharmaceutical product launches and drug approvals from 1,633 unique eHCP authors from around the world. 


Top 50: https://creation.co/resources/hcp-insight-trackers/top-50-pharma-tracker/
Product approval: https://creation.co/resources/hcp-insight-trackers/product-launch-tracker/
All trackers: https://creation.co/resources/hcp-insight-trackers/


View all articles >

Meet the Author

Alexandra Maria Chatziioannidou

As a Biological Sciences graduate, Alexandra is passionate about making an impact in the healthcare industry through creating actionable insights and telling stories with data from online healthcare conversations.

Alexandra loves spending quality time with friends and family, both in the UK and back home in Greece, on her holidays. She also enjoys exploring new places!

Suggested next

05.01.2024 | Article

Product Launch Tracker: Hundreds of eHCPs are enthusiastic about the first Sickle Cell Disease gene therapies.

Discover which new drug approvals HCPs are talking about

By Alexandra Maria Chatziioannidou

Breaking from tradition: how social media can improve doctors’ congress experience

13.06.2019 | Article

Breaking from tradition: how social media can improve doctors’ congress experience

Breaking from tradition: how social media can improve doctors’ congress experience

By Suzanna Gamwell

View all articles >